The sirtuin family's role in aging and age-associated pathologies

Journal of Clinical Investigation

Volumn 123, Issue 3, 2013, Pages 973-979

  Hall, Jessica A ^a   Dominy, John E ^a   Lee, Yoonjin ^a   Puigserver, Pere ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CARBAMOYL PHOSPHATE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN; SIRTUIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADIPOGENESIS; AGING; BASAL METABOLIC RATE; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC STRESS; COLON CARCINOMA; DEACETYLATION; DEMYELINATING NEUROPATHY; DNA DAMAGE; DNA REPAIR; ENERGY EXPENDITURE; FATTY ACID OXIDATION; FATTY LIVER; FIBROSING ALVEOLITIS; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEART HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HETEROCHROMATIN; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFE EXTENSION; LIFESTYLE MODIFICATION; LONGEVITY; METABOLIC SYNDROME X; MITOCHONDRIAL PERMEABILITY; NERVE DEGENERATION; NERVE FIBER DEGENERATION; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PHYSICAL ACTIVITY; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SKIN CARCINOMA; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; WHITE ADIPOSE TISSUE;

AGING; ANIMALS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; NEOPLASMS; NEURODEGENERATIVE DISEASES; SIRTUINS;

EID: 84874594425     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64094     Document Type: Review

References (125)

1. Koubova J, Guarente L. How does calorie restriction work? Genes Dev. 2003;17(3):313-321. (Pubitemid 36182188)
2. Mattison JA, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature. 2012;489(7415):318-321.
3. Colman RJ, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325(5937):201-204.
4. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999;13(19):2570-2580. (Pubitemid 29489648)
5. Chen D, Guarente L. SIR2: a potential target for calorie restriction mimetics. Trends Mol Med. 2007; 13(2):64-71. (Pubitemid 46186153)
6. Burnett C, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 2011;477(7365):482-485.
7. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793-798. (Pubitemid 30599063)
8. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225-238.
9. Haigis MC, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006;126(5):941-954. (Pubitemid 44321935)
10. Du J, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334(6057):806-809.
11. Peng C, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011;10(12):M111.012658.
12. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol. 2012;13(4):270-276.
13. Hirschey MD, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121-125.
14. Kim SC, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006;23(4):607-618. (Pubitemid 44205490)
15. Yang L, et al. The fasted/fed mouse metabolic acetylome: N6-acetylation differences suggest acetylation coordinates organ-specific fuel switching. J Proteome Res. 2011;10(9):4134-4149.
16. Herranz D, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.
17. Mostoslavsky R, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315-329. (Pubitemid 43121980)
18. Kanfi Y, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-221.
19. Bellizzi D, et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics. 2007; 89(1):143-150. (Pubitemid 44856231)
20. Bellizzi D, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics. 2005;85(2):258-263. (Pubitemid 40164791)
21. Rose G, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003; 38(10):1065-1070. (Pubitemid 37324417)
22. Lescai F, et al. Human longevity and 11p15.5: a study in 1321 centenarians. Eur J Hum Genet. 2009; 17(11):1515-1519.
23. Dittenhafer-Reed KE, Feldman JL, Denu JM. Catalysis and mechanistic insights into sirtuin activation. Chembiochem. 2011;12(2):281-289.
24. Grinker JA, Tucker K, Vokonas PS, Rush D. Body habitus changes among adult males from the normative aging study: relations to aging, smoking history and alcohol intake. Obes Res. 1995;3(5):435-446.
25. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5(7):367-373.
26. Dominy JE, Gerhart-Hines Z, Puigserver P. Nutrient-dependent acetylation controls basic regulatory metabolic switches and cellular reprogramming. Cold Spring Harb Symp Quant Biol. 2011;76:203-209.
27. Gerhart-Hines Z, et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell. 2011;44(6):851-863.
28. Gerhart-Hines Z, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007; 26(7):1913-1923. (Pubitemid 46624046)
29. Canto C, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
30. Qiang L, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell. 2012;150(3):620-632.
31. Kajimura S, et al. Regulation of the brown and white fat gene programs through a PRDM16/ CtBP transcriptional complex. Genes Dev. 2008; 22(10):1397-1409. (Pubitemid 351717529)
32. Banks AS, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008;8(4):333-341.
33. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat dietinduced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793-9798. (Pubitemid 352031379)
34. Moynihan KA, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucosestimulated insulin secretion in mice. Cell Metab. 2005;2(2):105-117.
35. Tang MM, et al. Intra-arterial targeted islet-specific expression of Sirt1 protects beta cells from streptozotocin-induced apoptosis in mice. Mol Ther. 2011; 19(1):60-66.
36. Gillum MP, et al. SirT1 regulates adipose tissue inflammation. Diabetes. 2011;60(12):3235-3245.
37. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327-338.
38. Wang RH, Li C, Deng CX. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci. 2010;6(7):682-690.
39. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712-716. (Pubitemid 350207685)
40. Feige JN, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8(5):347-358.
41. Minor RK, et al. SRT1720 improves survival and healthspan of obese mice. Sci Rep. 2011;1:70.
42. Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
43. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012;11(6):443-461.
44. Blum CA, Ellis JL, Loh C, Ng PY, Perni RB, Stein RL. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem. 2011; 54(2):417-432.
45. Erion DM, et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A. 2009;106(27):11288-11293.
46. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci U S A. 2007;104(31):12861-12866. (Pubitemid 47255245)
47. Qiang L, Lin HV, Kim-Muller JY, Welch CL, Gu W, Accili D. Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation. Cell Metab. 2011;14(6):758-767.
48. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28(1):91-106. (Pubitemid 47531974)
49. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell. 2007;6(4):505-514. (Pubitemid 47087055)
50. Krishnan J, et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev. 2012;26(3):259-270.
51. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/ deacetylation. Cell Metab. 2007;6(2):105-114. (Pubitemid 47163621)
52. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma. Mol Biol Cell. 2009;20(3):801-808.
53. Lombard DB, Tishkoff DX, Bao J. Mitochondrial sirtuins in the regulation of mitochondrial activity and metabolic adaptation. Handb Exp Pharmacol. 2011;206:163-188.
54. Palacios OM, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY). 2009;1(9):771-783.
55. Schwer B, et al. Calorie restriction alters mitochondrial protein acetylation. Aging Cell. 2009;8(5):604-606.
56. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280(14):13560-13567. (Pubitemid 40517248)
57. Bao J, et al. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic Biol Med. 2010;49(7):1230-1237.
58. Kendrick AA, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011;433(3):505-514.
59. Hirschey MD, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011;44(2):177-190.
60. Jing E, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci U S A. 2011; 108(35):14608-14613.
61. Yechoor VK, et al. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci U S A. 2004;101(47):16525-16530. (Pubitemid 39557746)
62. Shimazu T, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3- methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010;12(6):654-661.
63. Ahn BH, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A. 2008;105(38):14447- 14452.
64. Kim HS, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41-52.
65. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry. 2010;49(2):304-311.
66. Fernandez-Marcos PJ, et al. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep. 2012;2:425.
67. Nasrin N, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem. 2010;285(42):31995- 32002.
68. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137(3):560-570.
69. Lombard DB, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807-8814.
70. Zhong L, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010;140(2):280-293.
71. Kim HS, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 2010;12(3):224-236.
72. Schwer B, et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci U S A. 2010;107(50):21790-21794.
73. Kanfi Y, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell. 2010;9(2):162-173.
74. Kawahara TL, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 2009; 136(1):62-74.
75. Kaidi A, Weinert BT, Choudhary C, Jackson SP. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science. 2010; 329(5997):1348-1353.
76. Yang B, Zwaans BM, Eckersdorff M, Lombard DB. The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle. 2009;8(16):2662-2663.
77. Michishita E, et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle. 2009;8(16):2664-2666.
78. Alcendor RR, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007;100(10):1512-1521. (Pubitemid 46834764)
79. Zhang QJ, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008;80(2):191-199.
80. Stein S, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 2010;31(18):2301-2309.
81. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3adependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758-2771.
82. Hafner AV, et al. Regulation of the mPTP by SIRT3- mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010;2(12):914-923.
83. Vakhrusheva O, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008;102(6):703-710. (Pubitemid 351457857)
84. Huffman DM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612-6618. (Pubitemid 47105506)
85. Bradbury CA, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005; 19(10):1751-1759. (Pubitemid 41486152)
86. Stunkel W, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007;2(11):1360-1368. (Pubitemid 350176266)
87. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007;299(2):103-106. (Pubitemid 46669407)
88. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005;65(22):10457-10463. (Pubitemid 41743740)
89. Heltweg B, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66(8):4368-4377.
90. Ota H, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25(2):176-185. (Pubitemid 43083679)
91. Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13(5):454-463. (Pubitemid 351609441)
92. Suzuki K, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncology reports. 2012; 27(6):1726-1732.
93. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett. 2011;306(1):10-14.
94. Wang RH, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008;32(1):11-20.
95. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6):864-878.
96. Firestein R, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PloS One. 2008;3(4):e2020.
97. Wang RH, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14(4):312-323.
98. Herranz D, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.
99. North BJ, Verdin E. Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J Biol Chem. 2007;282(27):19546-19555. (Pubitemid 47100062)
100. Pandithage R, et al. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 2008;180(5):915-929. (Pubitemid 351398419)
101. Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 2003;23(9):3173-3185. (Pubitemid 36459231)
102. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/ p300-mediated acetylation of histone H3 on lysine 56. Nature. 2009;459(7243):113-117.
103. Vaquero A, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006;20(10):1256-1261. (Pubitemid 43727586)
104. Kim HS, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487-499.
105. Jin YH, et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 2008;368(3):690-695.
106. Haigis MC, Deng CX, Finley LW, Kim HS, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012;72(10):2468-2472.
107. Tao R, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010; 40(6):893-904.
108. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010; 12(6):662-667.
109. Finley LW, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19(3):416-428.
110. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816(1):80-88.
111. Mao Z, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011; 332(6036):1443-1446.
112. Barber MF, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487(7405):114-118.
113. Seligson DB, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174(5):1619-1628.
114. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010; 142(2):320-332.
115. Jeong H, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2012; 18(1):159-165.
116. Jiang M, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med. 2012;18(1):153-158.
117. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32(1):124-132.
118. Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci. 2006;26(33):8484-8491. (Pubitemid 44316176)
119. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305(5686):1010-1013. (Pubitemid 39071777)
120. Pallos J, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet. 2008;17(23):3767-3775.
121. Luthi-Carter R, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A. 2010;107(17):7927- 7932.
122. Outeiro TF, et al. Sirtuin 2 inhibitors rescue alphasynuclein-mediated toxicity in models of Parkinson's disease. Science. 2007;317(5837):516-519. (Pubitemid 47196116)
123. Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One. 2012;7(4):e34805.
124. Beirowski B, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci U S A. 2011;108(43):E952-E961.
125. Someya S, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010;143(5):802-812.